NEW YORK, August 12, 2022--Pfizer Inc. (NYSE:PFE) today announced positive top-line results from its pivotal U.S. Phase 3 study (NCT04382326) in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes contained in the vaccine for the pediatric population.
What happened Shares of Pfizer (NYSE: PFE) slipped 3.3% lower as of the market close on Thursday. The decline resulted from investors' concerns about litigation related to Zantac. The U.S. Food and Drug Administration (FDA) called for the heartburn drug to be pulled from the market in 2020 due to safety concerns.
Novavax missed Wall Street expectations but remains optimistic about the fourth quarter and 2023.